RheumNow

Cycling vs Switching after TNFi Failure in axSpA Dr. Lihi Eder discusses abstract 0603, presented at #ACR24

SELECT-GCA: Efficacy and Safety of Upadacitinib Dr. Richard Conway discusses abstract 0770, presented at #ACR24

ACR24 SpA Topic Panel: Key Discussions on Spondyloarthritis Join us as we dive into expert insights from the ACR Annual Meeting! This special panel will focus on the latest research and advancements in Spondyloarthritis (SpA), featuring thought leaders in the field.

Aging Gracefully in Managing Rheumatic Diseases Dr. Mrinalini Dey and Dr. Elena Myasoedova review highlights from a session on aging presented at #ACR24.

A new score to quantify GCA inflammation? The treatment paradigm for Giant Cell Arteritis (GCA) has been a binary approach to the presence or absence of vasculitis. When GCA is present, we institute high doses of glucocorticoids for treatment of the inflammatory process. #ACR24

Up-front Secukinumab in PsA? We now have an absolute plethora of agents available for use in psoriatic arthritis (PsA). In contrast we have an almost complete lack of understanding of how best to optimise use of these agents – what is the right agent at the right time for the right patient. #ACR24

Gender Differences in SpA #ACR24 provided its attendees with vast information about disease pathophysiology, diagnosis and treatment covering both clinical and basic sciences. One of the hot topics during the meeting was gender differences in SpA. Three abstracts presented addressed issues related to these differences particularly in the aspects of treatment response and disease activity.

Changing Mindsets about Methotrexate Side Effects Dr. Mrinalini Dey discusses abstract 1676, presented at #ACR24.

Health Literacy: the forgotten social determinant of health? Nine out of ten adults in the USA struggle to understand basic health-related information (1). Across the pond, in the UK, 7.1 million adults read at, or below, the level of a nine-year-old, with 60% unable to understand health information. #ACR24 https://buff.ly/4eDs3yr

JAK inhibitors in GCA? We have a phase 3 trial in giant cell arteritis back on the opening day plenary stage. The SELECT-GCA study, looking at upadacitinib in GCA, was scheduled to anchor the #ACR24 opening plenary for a reason - it is highly notable and badly needed. https://buff.ly/3B1hNSU